BCG Treatment for Bladder Cancer: How It Works

BCG, short for Bacillus Calmette-Guérin, is a live but weakened strain of the bacterium that causes tuberculosis in cattle. When instilled directly into the bladder through a catheter, it provokes a powerful local immune response that destroys cancer cells and prevents tumors from returning. It has been the gold-standard immunotherapy for non-muscle-invasive bladder cancer (NMIBC) since the late 1970s, and it remains one of the most successful examples of cancer immunotherapy in all of medicine, predating the modern checkpoint-inhibitor era by decades.

From Tuberculosis Vaccine to Cancer Treatment

The path from TB prevention to bladder cancer therapy was not a straight line. Researchers noticed as far back as the early twentieth century that patients with tuberculosis seemed to develop certain cancers less often. That observation, combined with laboratory work showing that BCG could trigger immune reactions strong enough to inhibit tumor growth in animal models, eventually led to human clinical trials. Those trials demonstrated that BCG instilled directly into the bladder could both eradicate existing superficial tumors and prevent new ones from forming.¹ Today BCG immunotherapy is recommended for intermediate- and high-risk NMIBC after surgical removal of visible tumor tissue, a procedure called transurethral resection.

How BCG Attaches to the Bladder Wall

The treatment begins with a simple but carefully timed procedure. A nurse or urologist threads a thin catheter into the bladder and instills a liquid suspension containing live BCG bacteria. You hold the solution in your bladder for about two hours, then urinate it out. During that dwell time, the bacteria need to physically stick to the inner lining of the bladder to do their work.

That attachment depends on a protein called fibronectin, which is naturally present on the bladder’s surface, especially after the minor tissue damage caused by tumor resection. In laboratory and animal studies, BCG bacteria bound specifically to fibronectin-coated surfaces and did not attach to other structural proteins like laminin or collagen. When researchers blocked fibronectin with antibodies, BCG attachment to damaged bladder surfaces dropped by more than 95%.² This is one reason doctors wait a couple of weeks after tumor resection before starting BCG: the healing wound exposes fibronectin, giving the bacteria a foothold, but the tissue needs to be intact enough that the bacteria stay local rather than entering the bloodstream.

Kicking Off the Immune Response

Once BCG bacteria bind to the bladder lining, the cells that line the urinary tract are the first to react. These uroepithelial cells carry molecular sensors on their surface, including receptors known as toll-like receptors. BCG activates two of these in particular, TLR2 and TLR4, which function as alarm bells for the innate immune system.³ Laboratory studies have confirmed that uroepithelial cells express several of these receptors and that activation causes the cells to release signaling molecules called cytokines, including interleukin-6 and interleukin-8, which recruit immune cells to the area.⁴

This initial wave of immune activity brings in neutrophils, macrophages, and natural killer cells, all of which attack both the bacteria and nearby cancer cells. But the real heavy lifting comes from the adaptive immune system, specifically a class of helper T cells that drive what researchers call a Th1 response. This type of immune activation is characterized by the release of interferon-gamma, a cytokine that ramps up the killing power of immune cells and helps them identify and destroy tumor cells.⁵ A robust Th1 response appears to be essential for BCG treatment to succeed.⁶ Both the innate and adaptive arms of the immune system ultimately contribute to tumor destruction.⁷

Trained Immunity and Effects Beyond the Bladder

One of the more fascinating discoveries about BCG in recent years is that it does not just teach the adaptive immune system to recognize threats. It also reprograms cells of the innate immune system through a process called trained immunity. Normally, innate immune cells like monocytes are considered non-specific: they respond to threats broadly rather than remembering specific pathogens. BCG appears to change that by altering the chemical marks on the DNA packaging inside these cells, essentially loosening or tightening access to genes that control inflammation. After BCG exposure, monocytes produce higher levels of key inflammatory signals when they encounter unrelated pathogens later on.⁸

Research into re-engineered BCG strains has explored ways to amplify this trained immunity effect. One approach involves overexpressing a molecule called cyclic di-AMP in the BCG bacteria, which led to greater changes in the activating epigenetic marks on monocyte DNA compared to standard BCG, both at rest and after re-stimulation.⁹ While this strain is still experimental, it highlights how central trained immunity has become to the field’s understanding of why BCG works.

This systemic immune priming has practical consequences beyond cancer. In patients receiving intravesical BCG for bladder cancer, researchers found roughly a 37% decreased risk of respiratory infections compared to similar patients who did not receive BCG, likely because of the heightened innate immune readiness.⁸

How Well BCG Works and Why Maintenance Matters

BCG is effective at reducing both tumor recurrence and the risk of a superficial cancer progressing into the muscle wall of the bladder.⁷ Long-term data bear this out: in a study following high-risk patients for 15 years, those who received BCG had a 60% reduction in recurrence risk and roughly a 48% reduction in the risk of progression compared to those who did not receive it.¹⁰

Getting those results, however, requires more than the initial treatment course. A standard induction regimen consists of six weekly instillations, but maintenance therapy, in which additional instillations are given at scheduled intervals over one to three years, is what separates good outcomes from the best outcomes. Well-designed trials and meta-analyses have shown that maintenance BCG is significantly better than both induction alone and intravesical chemotherapy at reducing recurrence, progression, and mortality.¹¹ A network meta-analysis comparing different maintenance durations found that patients receiving no maintenance had about twice the recurrence rate of those receiving longer maintenance schedules, confirming that skipping maintenance substantially weakens the benefit.¹²

Side Effects and When to Worry

Because BCG works by provoking a strong immune reaction, side effects are extremely common. Most people experience bladder irritation, urinary urgency and frequency, mild blood in the urine, and a general flu-like feeling with low-grade fever. These symptoms typically peak in the first 48 hours after an instillation and resolve within a few days. Cystitis, or inflammation of the bladder lining, is the most frequently reported adverse effect, occurring in roughly 40% of patients in one series.¹³ About 8% of patients ultimately need to stop treatment because side effects become intolerable.¹⁴

Severe complications are rare but serious. The most dangerous is disseminated BCG infection, sometimes called BCGitis or BCG sepsis, in which the live bacteria spread beyond the bladder. This can present as persistent high fevers, organ involvement, or a clinical picture resembling tuberculosis. In a pooled analysis of nearly 300 cases, disseminated infection was the most common form of systemic BCG disease, followed by genitourinary and bone or joint involvement.¹⁵ Treatment involves anti-tuberculosis drugs, typically a three-drug regimen for about six months, and the recovery rate is very high when treatment starts promptly.¹⁶ Because confirming BCG infection with lab cultures is slow and unreliable, clinicians are advised not to wait for laboratory confirmation before starting antituberculosis treatment when the clinical suspicion is high.¹⁷

Quality of Life During Treatment

The side-effect profile matters not just medically but practically. A systematic review examining quality of life during intravesical therapy found that frequent instillations were tied to increased urinary symptoms, fatigue, and emotional distress. Withdrawal rates in intensive schedules ran very high, with up to 90% of patients dropping out during the first year because of the treatment burden and side effects. Reducing the frequency of instillations appears to preserve treatment benefit while improving both quality of life and adherence.¹⁸ This finding has influenced how many urologists structure maintenance schedules, trying to balance maximum cancer control with a regimen patients can actually tolerate for years.

The BCG Shortage and Whether Reduced Doses Work

A recurring challenge in the BCG world is supply. Because the treatment uses a live biological product manufactured under strict conditions, global shortages have hit repeatedly over the past decade, forcing clinicians to stretch limited supplies. One common approach is to reduce the dose to one-third of the standard amount. A large real-world study from a tertiary cancer center found that one-third dose BCG did not adversely affect time to recurrence, time to progression, or cancer-specific survival compared to full-dose treatment.¹⁹

A broader meta-analysis including over 3,700 patients added nuance: reduced-dose BCG was associated with a modestly higher recurrence rate overall, but the increased risk appeared primarily in patients receiving induction therapy alone. When maintenance therapy was used alongside the reduced dose, the difference in recurrence evaporated. The reduced dose also came with fewer episodes of fever and fewer patients needing to discontinue treatment.²⁰ The practical takeaway is that during shortages, a lower dose with proper maintenance is a reasonable compromise, and for some patients it may actually improve adherence by reducing side effects.

Predicting Who Will Respond

Not everyone responds to BCG. Roughly 30 to 40% of patients experience recurrence despite treatment, and identifying those patients early would allow doctors to switch strategies sooner. Several lines of research are pursuing predictive biomarkers, though none has reached routine clinical use yet.

One approach looks at cytokines in the urine during treatment. A panel of nine cytokines measured in urine samples, combined into a predictive tool called CyPRIT, was able to predict the likelihood of tumor recurrence with about 85% accuracy.²¹ A separate study identified a different set of urinary markers, including changes in interleukin-8 and interferon-gamma-induced protein-10, that predicted time to recurrence.²² Blood-based biomarkers are being studied as well: serum levels of the chemokine CCL27, measured before treatment and tracked over time, showed promise in distinguishing responders from non-responders, with a combined score achieving about 90% predictive accuracy in a validation set.²³

An older and more accessible idea is the tuberculin skin test (also called the Mantoux or PPD test), which measures a person’s existing immune reactivity to tuberculosis-related proteins. Some studies found that patients with a strongly positive skin test before treatment had substantially better recurrence-free survival, with one study reporting an 89% five-year recurrence-free survival in strongly positive patients compared to about 56% in those who were negative.²⁴ Another study also found lower pre-treatment PPD values in patients who later recurred.²⁵ However, the picture is not settled. A separate study specifically designed to test the skin test’s predictive value found no association with recurrence-free survival, progression-free survival, or treatment toxicity across any tumor subgroup.²⁶ The discrepancy may reflect differences in study populations, the cutoff values used to define a “positive” test, or how broadly the immune system’s pre-existing TB-related memory actually matters to the local bladder response. For now, the skin test remains an interesting signal but not a clinically validated decision tool.

What Happens When BCG Fails

When tumors recur despite adequate BCG therapy, the situation changes. The traditional next step has been radical cystectomy, surgical removal of the entire bladder. That is a major operation with lifelong consequences, so there has been intense interest in bladder-sparing alternatives.

Three FDA-approved options now exist for patients with BCG-unresponsive disease. Pembrolizumab, a checkpoint inhibitor that blocks PD-1, was the first approved agent in this space, though its one-year response rate of about 19% limits its appeal. Nadofaragene firadenovec is the first approved intravesical gene therapy, with a one-year response rate of around 24% and some patients maintaining bladder preservation out to five years. The newest agent, nogapendekin alfa-inbakicept, is an immune-stimulating protein used alongside BCG that has shown the highest reported one-year complete response rate at roughly 45%.²⁷ Outside of approved drugs, many urologists also use a combination of gemcitabine and docetaxel off-label as a salvage regimen because of its low cost and generally tolerable side effects.

Interestingly, research into why BCG fails has found that PD-L1, a protein that helps tumors hide from the immune system, is expressed more often in tumors that recur after BCG than in tumors that have never been exposed to it. In one study, about 14% of post-BCG recurrences were PD-L1 positive compared to 7% of BCG-naive tumors. Looking at matched tissue from the same patients before and after BCG, 18 out of 19 tumors that became PD-L1 positive after treatment had been PD-L1 negative beforehand.²⁸ This suggests that BCG therapy itself may sometimes push tumors toward immune evasion, potentially making them candidates for checkpoint-inhibitor drugs designed to block PD-L1.

The Urinary Microbiome Connection

An emerging and admittedly early area of research involves the community of microbes naturally present in the urinary tract. The bladder was long assumed to be sterile, but modern sequencing techniques have revealed a resident microbial population. A study comparing the urinary microbiomes of BCG responders and non-responders found that the two groups had different microbial compositions. Responders harbored higher levels of two Bifidobacterium species, bacteria more commonly associated with the gut but increasingly recognized in the urinary tract, and these species were linked to longer recurrence-free survival. Responders also showed higher levels of quinolone synthesis in their urinary metabolic profile.²⁹ Whether these microbial differences are a cause or a consequence of BCG response remains unclear, but they open the door to the intriguing possibility that the local microbial environment could one day be manipulated to improve treatment outcomes.